Efficacy of sustained release of rhTM from the hydrogel for the treatment of diabetic wounds

Sustained release of recombinant thrombomodulin from cross-linked gelatinhyaluronic acid hydrogels potentiate wound healing in diabetic mice.

Article specifications

This clinical trial was published in 2018 in Journal of Eur J Pharm Biopharm. (IF 2013:4.245) by Taiwan specialists. In this study, we developed the biodegradable hydrogels and evaluated the efficacy of sustained release of rhTM from the hydrogel for the treatment of diabetic wounds. The hydrogels were composed of gelatin with or without hyaluronic acid, and fabricated by chemical cross-linking followed by lyophilization. The once every-3-day rhTM-loaded hydrogel (with hyaluronic acid) markedly promoted wound healing and were superior to rhTM solution, once daily rhTM hydrogel (without hyaluronic acid), hydrogel controls, and once every-3-day rhEGF hydrogel treatment groups.

 

Results

The rhTM hydrogels enhanced granulation tissue formation, re-epithelialization, collagen deposition, and angiogenesis in wound repair. The once every-3-day rhTM hydrogel was stable and drug release was maintained up to 11-month of storage at 4°C. The developed rhTM hydrogels could meet the needs for clinical practice, and may have future medical applications for wound care in diabetic patients.